AstraZeneca (AZN) Earnings Preview: Growth Momentum Meets High Expectations
Key Takeaways
-
Q4 2025 estimates: Revenue ~$15.7B, EPS $2.18, reflecting continued 9M growth.
-
Full-year guidance: Total revenue expected to grow high single digits (CER); 9M revenue already up 11%.
-
Core EPS: Low double-digit growth guidance, following 15% increase to $7.04 in first nine months.
-
Drivers: Oncology blockbusters Tagrisso and Imfinzi, and CVRM therapy Farxiga, sustaining momentum.
-
Investor focus: Pipeline readouts, 2026 guidance, and emerging market demand.
-
Market reaction: Q3 beat in November 2025 lifted shares 4.6%, highlighting positive sentiment.
Earnings Context
(AZN) AstraZeneca’s full-year 2025 results, set for February 10, 2026, cap a year of sustained growth amid competitive pressures. Following 21% total revenue growth in FY 2024 and 19% core EPS expansion, AZN has maintained momentum with 11% revenue growth through nine months of 2025. The report offers insight into:
-
Oncology leadership and pipeline execution
-
CVRM resilience and rare disease expansion
-
Margin trends, U.S. manufacturing investments, and patent cliff mitigation
For investors, Q4 results provide clarity on execution, operational leverage, and mid-teens growth potential through 2030.
Q4 2025 Expectations
-
Revenue: ~$15.7B, up from prior year
-
EPS: $2.18 consensus
-
Full-year: $58–59B total revenue (high single-digit CER growth), low double-digit core EPS growth
Key focus areas:
-
Oncology revenue: +16% YTD to $18.6B, driven by Tagrisso and Imfinzi
-
CVRM growth: Farxiga up 11% YTD
-
Rare disease: Ultomiris expansion offsets Soliris decline
Historical beats, like Q3’s $15.2B revenue and $2.38 core EPS, indicate potential upside, though currency volatility remains a consideration.
Market Sentiment & Technical Perspective
Post-Q3, investors are cautiously optimistic. Analysts highlight strong oncology demand and reaffirmed guidance, while risks include U.S. pricing pressures and regulatory scrutiny in China. Historical post-earnings moves average ~1.8% upward, with option flows and institutional positioning suggesting measured confidence.
AI trading tools: Trend Trader for Beginners: Strategy for Large Cap Stocks, 60 min, (TA) identifies short- to medium-term trends for large-cap pharma like AZN, emphasizing low-risk entries and capturing post-earnings momentum. Backtested success rates exceed 60% for similar scenarios.
Forward Outlook
Post-Q4, focus turns to 2026 guidance and pipeline execution:
-
Revenue growth expected in the high teens, supported by $50B U.S. investment in manufacturing and R&D
-
16 Phase III readouts in 9M 2025 drive approvals for Enhertu, Imfinzi, and Truqap
-
Therapy area dynamics:
-
Oncology: Tagrisso $5.4B sales, competitive landscape
-
CVRM: Farxiga +11%, SGLT2 margins under watch
-
Rare disease: Ultomiris expansion offsetting Soliris decline
-
Additional factors: Core tax rate 18–22%, forex impacts, emerging market demand, and regulatory progress on baxdrostat and datopotamab deruxtecan. Balanced execution across these areas supports AZN’s growth trajectory toward 2030, with pipeline success and loss-of-exclusivity mitigation critical to sustained performance.
Disclaimers and Limitations
AZN in -1.29% downward trend, declining for three consecutive days on August 14, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where AZN declined for three days, in of 267 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AZN as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AZN turned negative on August 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for AZN crossed bearishly below the 50-day moving average on July 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Aroon Indicator for AZN entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AZN's RSI Oscillator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in of 340 cases, the price rose further within the following month. The odds of a continued upward trend are .
AZN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.824) is normal, around the industry mean (19.641). P/E Ratio (23.421) is within average values for comparable stocks, (31.470). Projected Growth (PEG Ratio) (1.351) is also within normal values, averaging (11.358). Dividend Yield (0.020) settles around the average of (0.029) among similar stocks. P/S Ratio (3.984) is also within normal values, averaging (4.082).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AZN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement